Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Clinical Oncology

• Publication date

  2001-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2001.19.5.1304PMID 11230472
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.

  2000cited by this paper
• Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer.

  1999cited by this paper
• Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

  1999cited by this paper
• Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.

  1998cited by this paper
• Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials.

  1998cited by this paper
• Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.

  1996cited by this paper
• How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

  1996cited by this paper
• Clinical trials in relapsed prostate cancer: defining the target.

  1996cited by this paper
• Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

  1996cited by this paper
• Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.

  1995cited by this paper
• The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

  1995cited by this paper
• Pain assessment: global use of the Brief Pain Inventory.

  1994cited by this paper
• Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B.

  1993cited by this paper
• Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.

  1993cited by this paper
• Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

  1993cited by this paper
• Quality of life and treatment of hormone resistant metastatic prostatic cancer. The EORTC Genito-Urinary Group.

  1990cited by this paper
• Quality of life and treatment of hormone resistant metastatic prostatic cancer

  1990cited by this paper
• Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.

  1989cited by this paper
• Surrogate endpoints in clinical trials: definition and operational criteria.

  1989cited by this paper
• Analysis of survival by tumor response.

  1983cited by this paper
• Regression models and life tables (with discussion

  1972cited by this paper

• The Role of Prostate‐Specific Antigen (PSA) and PSA Kinetics in the Management of Advanced Prostate Cancer

  2016cites this paper
• The use of circulating biomarkers in early clinical trials in patients with cancer.

  2015cites this paper
• [Management of non metastatic castration resistant prostate cancer].

  2015cites this paper
• Verläufe ambulanter Docetaxel-Firstline-Chemotherapien bei Patienten mit kastrationsresistentem Prostatakarzinom

  2014cites this paper
• Effect of chronic Sildenafil treatment on the prostate of C57Bl/6 mice.

  2014cites this paper
• Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.

  2014cites this paper
• Prostate-Specific Antigen Kinetics under Androgen Deprivation Therapy and Prostate Cancer Prognosis

  2013cites this paper
• Study of the copolymer structure effect on physicochemical characteristics and in vitro stability of PLGA–PEG nanoparticles loaded 9-nitrocamptothecin

  2013cites this paper
• Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy.

  2013cites this paper
• Cabazitaxel for Metastatic Castrate-Resistant Prostate Cancer: A Case Presentation

  2012cites this paper
• Treatment Options in Hormone-Refractory Prostate Cancer

  2012cites this paper
• Ketoconazole in Taiwanese castration-resistant prostate cancer patients: Evaluation of response rates, durations, and predictors

  2012cites this paper
• Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer

  2011cites this paper
• Advanced prostate cancer: new agents, new questions.

  2011influential citation
• Therapeutic vaccines for prostate cancer.

  2010cites this paper
• Dendritic-cell vaccination for prostate cancer.

  2009cites this paper
• CARCINOMA DELLA PROSTATA

  2009cites this paper
• Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study.

  2009cites this paper
• Prostate‐specific antigen kinetics in localized and advanced prostate cancer

  2009cites this paper
• Prostate specific antigen best practice statement: 2009 update.

  2009cites this paper
• Multizentrische Therapieoptimierungsstudie zum Einsatz von Docetaxel (Taxotere®) und Mitoxantron (Novantron®) in der Therapie des hormonrefraktären Prostatakarzinoms

  2008cites this paper
• Circulating tumor markers.

  2008cites this paper
• About sorafenib in castration-resistant prostate cancer.

  2008cites this paper
• PSA et suivi après traitement du cancer de la prostate

  2008cites this paper
• [PSA and follow-up after treatment of prostate cancer].

  2008cites this paper
• Immunotherapy with dendritic cells for prostate cancer

  2007cites this paper
• Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient.

  2007cites this paper
• [Active immunotherapy of prostate cancer with a focus on dendritic cells].

  2007cites this paper
• Inmunoterapia activa en cáncer de próstata: Revisión con atención especial a las células dendríticas

  2007cites this paper
• Current indications for chemotherapy in prostate cancer patients.

  2007cites this paper
• Serum PSA half‐life as a predictor of survival for hormone‐refractory prostate cancer patients: Modelization using a standardized set of response criteria

  2007cites this paper
• Current perspectives in the treatment of advanced prostate cancer

  2007cites this paper
• Chemotherapy for hormone-resistant prostate cancer: Where are we today?

  2007influential citation
• Therapeutic vaccines for prostate cancer.

  2006cites this paper
• Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

  2006cites this paper
• Prostate‐specific antigen velocity and survival for patients with hormone‐refractory metastatic prostate carcinoma

  2006cites this paper
• Current status and perspective of antiangiogenic therapy for cancer: urinary cancer

  2006cites this paper
• Immunologic Approaches to Prostate Cancer

  2006cites this paper
• Immunotherapy for prostate cancer

  2006cites this paper
• Therapieoptionen des hormonrefraktären Prostatakarzinoms

  2005cites this paper
• Original article Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer

  2005cites this paper
• [Treatment options for hormone-refractory prostate cancer].

  2005cites this paper
• Erkenntnisse und Ergebnisse einer prospektiven klinischen Phase II Studie zur Chemotherapie des hormonrefraktären Prostatakarzinoms mit PEG-liposomalen Doxorubicin (Caelyx R )

  2005cites this paper
• Současný pohled na hormonálně refrakterní karcinom prostaty z hlediska přežití v závislosti na druhu terapie

  2005cites this paper
• [Therapy of hormone-refractory prostate cancer].

  2005cites this paper
• Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.

  2005cites this paper
• Advances in Prostate Cancer Chemotherapy: A New Era Begins 1

  2005cites this paper
• Therapie des hormonrefraktären Prostatakarzinoms

  2005cites this paper
• Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer

  2005cites this paper
• Prognostic model of event‐free survival for patients with androgen‐independent prostate carcinoma

  2005cites this paper
• Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer.

  2005cites this paper
• The natural history of androgen independent prostate cancer.

  2004cites this paper
• Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

  2004cites this paper
• Management of patients with hormone refractory prostate cancer.

  2004cites this paper
• Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).

  2004cites this paper
• Update on hormone-refractory prostate cancer

  2004cites this paper
• [Chemotherapy of the hormone-refractory prostate cancer].

  2004cites this paper
• Aktuelle Optionen der taxanbasierten Chemotherapie des hormonrefraktären Prostatakarzinoms

  2004cites this paper
• 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.

  2004cites this paper
• A Phase II trial of suramin monthly × 3 for hormone‐refractory prostate carcinoma

  2004cites this paper
• Stratégies thérapeutiques actuelles du cancer de la prostate hormonorésistant

  2004cites this paper
• Overview Management of Patients with Hormone Refractory Prostate Cancer

  2004cites this paper
• Therapieoptionen beim Prostatakarzinom

  2004cites this paper
• Chemotherapie beim hormonrefraktären Prostatakarzinom

  2003cites this paper
• Immunotherapy for prostate cancer

  2003cites this paper
• Using splines to detect changes in PSA doubling times

  2003cites this paper
• Bedeutung von Docetaxel für die Chemotherapie des hormonrefraktären Prostatakarzinoms

  2003cites this paper
• Chapter 46 – Androgen-independent Prostate Cancer: The Evolving Role of Chemotherapy

  2003cites this paper
• [Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer].

  2003cites this paper
• Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen‐independent prostate carcinoma

  2003cites this paper
• Current strategies in the management of hormone refractory prostate cancer.

  2003cites this paper
• Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.

  2003cites this paper
• [Chemotherapy of hormone refractory prostate carcinoma].

  2003cites this paper
• Endpoints in prostate cancer clinical trials.

  2002cites this paper
• Nomogram f or O verall S urvival o f P atients W ith Progressive M etastatic P rostate C ancer A fter C astration

  2002cites this paper
• Hormone-Refractory prostate cancer

  2002cites this paper
• Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration.

  2002cites this paper
• Highlights of contemporary issues in the medical management of prostate cancer.

  2002cites this paper
• Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response.

  2002cites this paper
• Novel clinical trials in androgen-independent prostate cancer.

  2002cites this paper
• Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.

  2002cites this paper
• Receptor gene messenger RNA expression in metastatic lesions of prostate cancer.

  2002cites this paper
• Prostate cancer update

  2002cites this paper
• Evidence in Advanced Disease: The Challenge for New Therapies

  2002cites this paper
• Bloodborne biomolecular markers in prostate cancer development and progression

  2002cites this paper
• Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine

  2002cites this paper
• "PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer.

  2002cites this paper
• Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.

  2002cites this paper
• Systemic treatment and new developments in advanced prostate cancer.

  2001cites this paper
• Immunotherapy for prostate cancer

  2001cites this paper
• Renal medicine and renal transplantation.

  2000cites this paper